FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits

AstraZeneca (NYSE:AZN) presented key data on the use of FARXIGA (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association (ADA) 78th Scientific Sessions this week in Orlando, FL, June 22-26, 2018. As quoted in the press release: These studies reinforce the use of dapagliflozin as a … Continued

More From BioPortfolio on "FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits"